6-Thioguanine Inhibits EV71 Replication by Targeting BIRC3-Mediated Autophagy

Study Background and Research Question

Enterovirus 71 (EV71) is a major causative agent of hand, foot, and mouth disease (HFMD), particularly affecting children under five in the Asia-Pacific region. While most cases are self-limiting, a subset can progress to severe neurological and cardiopulmonary complications, sometimes resulting in death. Despite the availability of effective vaccines in some regions, their narrow serotype coverage and the absence of a specific antiviral therapy highlight an ongoing clinical need. Previous studies suggested that 6-thioguanine (6-TG), a thiopurine class antineoplastic agent, possesses antiviral activity against other RNA viruses. However, its efficacy and mechanism of action against EV71 remained undefined, leading to the central research question: Can 6-TG inhibit EV71 replication, and if so, through which molecular pathways? (source: You et al., 2025).

Key Innovation from the Reference Study

The study by You et al. provides the first comprehensive mechanistic evidence that 6-TG robustly suppresses EV71 replication by downregulating BIRC3, a baculoviral IAP repeat-containing protein implicated in autophagy regulation. This establishes a novel link between BIRC3-mediated autophagy and EV71 pathogenesis, positioning 6-TG as a dual-function molecule with both antineoplastic and antiviral potential (source: You et al., 2025).

Methods and Experimental Design Insights

The investigators employed a combination of cell-based assays, molecular quantification, and mechanistic interrogation in human colorectal adenocarcinoma HT-29 cells. Key experimental approaches included:

• Quantification of EV71 mRNA by qPCR to assess viral replication.
• Western blot analysis of viral capsid protein VP1 to determine protein-level suppression.
• Viral titration assays to measure infectious progeny production.
• Cytotoxicity profiling (CC₅₀) and antiviral potency (IC₅₀) determination, allowing calculation of the selectivity index (SI).
• Protein and gene expression analysis of BIRC3 and autophagy markers to dissect the pathway involved.

This multifaceted approach enabled the authors to not only quantify the antiviral effects but also to delineate the molecular mechanism underlying 6-TG's activity (source: You et al., 2025).

Protocol Parameters

• cell proliferation assay | 2000 μM (CC₅₀ for 6-TG) | HT-29 cells | Defines upper cytotoxicity threshold for 6-TG in this model | paper
• antiviral assay | 0.9302 μM (IC₅₀ for EV71 inhibition by 6-TG) | HT-29 cells | Specifies potent antiviral concentration | paper
• selectivity index | >2150.1 (SI for 6-TG vs. EV71) | HT-29 cells | Indicates high therapeutic window compared to ribavirin (SI >66.7) | paper
• cell cycle regulation assay | workflow-dependent | cancer biology models | For comparison with established CDK inhibitors such as LEE011 succinate | workflow_recommendation

Core Findings and Why They Matter

The results demonstrated that 6-TG significantly reduced EV71 mRNA levels, VP1 protein expression, and viral progeny production in infected HT-29 cells. Notably, the compound exhibited a high CC₅₀ (>2000 μM) and a low IC₅₀ (0.9302 μM), yielding a selectivity index (SI) exceeding 2150—far surpassing that of ribavirin, a standard antiviral benchmark (SI >66.7; source: You et al., 2025). Mechanistically, 6-TG treatment led to decreased BIRC3 expression, which in turn suppressed autophagy—a cellular process previously implicated in EV71 replication. The attenuation of BIRC3-mediated autophagy likely disrupts viral lifecycle progression, offering a novel target for intervention.

These findings are significant for several reasons:

• The identification of BIRC3 as a key autophagy regulator in EV71 infection broadens our understanding of host-pathogen interactions.
• The exceptional selectivity index for 6-TG supports its candidacy for further translational research in EV71 and related viral infections.
• This study provides a rationale for repurposing established antineoplastic agents as antivirals, subject to careful toxicity and efficacy evaluation.

Comparison with Existing Internal Articles

Although the primary focus here is on antiviral mechanisms, parallels can be drawn with contemporary research in cell cycle and autophagy pathways in oncology. For example, internal work on Ribociclib succinate (LEE011 succinate) has highlighted the strategic inhibition of CDK4/6—a central axis in cell cycle regulation and cancer biology (internal_article). Like 6-TG, LEE011 succinate modulates key cellular processes (cell cycle progression for cancer, autophagy for EV71) via targeted inhibition. Both compounds serve as valuable tools for dissecting the role of host cell pathways in disease, though their domain applications differ.

Furthermore, scenario-driven guidance on employing Ribociclib succinate in cell proliferation and cytotoxicity assays (internal_article) reinforces the importance of integrating cytotoxicity profiling (CC₅₀) and selectivity index calculations—methodological principles also central to the present EV71 study.

Limitations and Transferability

While the study offers compelling in vitro evidence for the antiviral efficacy of 6-TG, several limitations merit consideration:

• Model system: All experiments were conducted in HT-29 cells; in vivo relevance requires further validation (source: You et al., 2025).
• Safety profile: As 6-TG is a cytotoxic antineoplastic agent, its therapeutic window for antiviral use in pediatric populations must be thoroughly assessed.
• Mechanistic scope: The focus was on BIRC3-mediated autophagy; additional host or viral factors may also contribute to the observed effects.

Thus, while this cross-domain bridge between oncology pharmacology and antiviral research is promising, direct clinical translation is premature without further preclinical and clinical evidence.

Why this cross-domain matters, maturity, and limitations

The intersection of cell cycle and autophagy regulation in both oncology and virology underlines the value of pharmacological agents that can modulate host cell pathways. However, the maturity of evidence for 6-TG as an antiviral remains at the preclinical, cell-based stage—unlike established CDK inhibitors in cancer research. This necessitates cautious optimism and underscores the need for rigorous translational pipelines.

Research Support Resources

For laboratories aiming to explore cell cycle regulation, autophagy, or viral replication dynamics, robust assay controls and pathway-specific inhibitors are critical. Ribociclib succinate (LEE011 succinate, SKU B1084) is a highly selective CDK4/6 inhibitor widely used in cancer research and cell proliferation assays (source: product_spec). Its validated solubility profile and storage recommendations make it suitable for workflow integration alongside cytotoxicity and pathway modulation studies. While this compound is not indicated for antiviral use, it provides a benchmark for mechanistic studies involving cell cycle and autophagy regulation. Researchers are encouraged to leverage such research-grade inhibitors as part of comparative or combinatorial screening platforms, always adhering to appropriate experimental context and safety standards (source: product_spec).